Abstract Background XTX101 is an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 designed to block CTLA-4 and deplete regulatory T cells upon activation in the tumor microenvironment by proteases. XTX101 also contains mutations designed to enhance Fcγ receptor binding and improve effector function.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with John
Contact John, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack